193 related articles for article (PubMed ID: 23349722)
1. Attenuation of Rhes activity significantly delays the appearance of behavioral symptoms in a mouse model of Huntington's disease.
Baiamonte BA; Lee FA; Brewer ST; Spano D; LaHoste GJ
PLoS One; 2013; 8(1):e53606. PubMed ID: 23349722
[TBL] [Abstract][Full Text] [Related]
2. Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington's disease.
Swarnkar S; Chen Y; Pryor WM; Shahani N; Page DT; Subramaniam S
Neurobiol Dis; 2015 Oct; 82():66-77. PubMed ID: 26048156
[TBL] [Abstract][Full Text] [Related]
3. Global Rhes knockout in the Q175 Huntington's disease mouse model.
Heikkinen T; Bragge T; Kuosmanen J; Parkkari T; Gustafsson S; Kwan M; Beltran J; Ghavami A; Subramaniam S; Shahani N; Ramírez-Jarquín UN; Park L; Muñoz-Sanjuán I; Marchionini DM
PLoS One; 2021; 16(10):e0258486. PubMed ID: 34648564
[TBL] [Abstract][Full Text] [Related]
4. The role of Rhes, Ras homolog enriched in striatum, in neurodegenerative processes.
Harrison LM; Lahoste GJ
Exp Cell Res; 2013 Sep; 319(15):2310-5. PubMed ID: 23583659
[TBL] [Abstract][Full Text] [Related]
5. Bioinformatics analysis of Ras homologue enriched in the striatum, a potential target for Huntington's disease therapy.
Carbo M; Brandi V; Pascarella G; Staid DS; Colotti G; Polticelli F; Ilari A; Morea V
Int J Mol Med; 2019 Dec; 44(6):2223-2233. PubMed ID: 31638189
[TBL] [Abstract][Full Text] [Related]
6. Huntington's disease is a disorder of the corpus striatum: focus on Rhes (Ras homologue enriched in the striatum).
Subramaniam S; Snyder SH
Neuropharmacology; 2011 Jun; 60(7-8):1187-92. PubMed ID: 21044641
[TBL] [Abstract][Full Text] [Related]
7. Neocortical expression of mutant huntingtin is not required for alterations in striatal gene expression or motor dysfunction in a transgenic mouse.
Brown TB; Bogush AI; Ehrlich ME
Hum Mol Genet; 2008 Oct; 17(20):3095-104. PubMed ID: 18632688
[TBL] [Abstract][Full Text] [Related]
8. Rhes suppression enhances disease phenotypes in Huntington's disease mice.
Lee JH; Sowada MJ; Boudreau RL; Aerts AM; Thedens DR; Nopoulos P; Davidson BL
J Huntingtons Dis; 2014; 3(1):65-71. PubMed ID: 25062765
[TBL] [Abstract][Full Text] [Related]
9. Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats.
Menalled LB; Sison JD; Dragatsis I; Zeitlin S; Chesselet MF
J Comp Neurol; 2003 Oct; 465(1):11-26. PubMed ID: 12926013
[TBL] [Abstract][Full Text] [Related]
10. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
[TBL] [Abstract][Full Text] [Related]
11. Striatal Induction and Spread of the Huntington's Disease Protein: A Novel Rhes Route.
Subramaniam S
J Huntingtons Dis; 2022; 11(3):281-290. PubMed ID: 35871361
[TBL] [Abstract][Full Text] [Related]
12. Rhes deletion is neuroprotective in the 3-nitropropionic acid model of Huntington's disease.
Mealer RG; Subramaniam S; Snyder SH
J Neurosci; 2013 Feb; 33(9):4206-10. PubMed ID: 23447628
[TBL] [Abstract][Full Text] [Related]
13. 2,4 DNP improves motor function, preserves medium spiny neuronal identity, and reduces oxidative stress in a mouse model of Huntington's disease.
Wu B; Jiang M; Peng Q; Li G; Hou Z; Milne GL; Mori S; Alonso R; Geisler JG; Duan W
Exp Neurol; 2017 Jul; 293():83-90. PubMed ID: 28359739
[TBL] [Abstract][Full Text] [Related]
14. Towards a transgenic model of Huntington's disease in a non-human primate.
Yang SH; Cheng PH; Banta H; Piotrowska-Nitsche K; Yang JJ; Cheng EC; Snyder B; Larkin K; Liu J; Orkin J; Fang ZH; Smith Y; Bachevalier J; Zola SM; Li SH; Li XJ; Chan AW
Nature; 2008 Jun; 453(7197):921-4. PubMed ID: 18488016
[TBL] [Abstract][Full Text] [Related]
15. Implantation of undifferentiated and pre-differentiated human neural stem cells in the R6/2 transgenic mouse model of Huntington's disease.
El-Akabawy G; Rattray I; Johansson SM; Gale R; Bates G; Modo M
BMC Neurosci; 2012 Aug; 13():97. PubMed ID: 22876937
[TBL] [Abstract][Full Text] [Related]
16. Wheel running from a juvenile age delays onset of specific motor deficits but does not alter protein aggregate density in a mouse model of Huntington's disease.
van Dellen A; Cordery PM; Spires TL; Blakemore C; Hannan AJ
BMC Neurosci; 2008 Apr; 9():34. PubMed ID: 18380890
[TBL] [Abstract][Full Text] [Related]
17. Significantly differential diffusion of neuropathological aggregates in the brain of transgenic mice carrying N-terminal mutant huntingtin fused with green fluorescent protein.
Cheng PH; Li CL; Her LS; Chang YF; Chan AW; Chen CM; Yang SH
Brain Struct Funct; 2013 Jan; 218(1):283-94. PubMed ID: 22422149
[TBL] [Abstract][Full Text] [Related]
18. Early white matter abnormalities, progressive brain pathology and motor deficits in a novel knock-in mouse model of Huntington's disease.
Jin J; Peng Q; Hou Z; Jiang M; Wang X; Langseth AJ; Tao M; Barker PB; Mori S; Bergles DE; Ross CA; Detloff PJ; Zhang J; Duan W
Hum Mol Genet; 2015 May; 24(9):2508-27. PubMed ID: 25609071
[TBL] [Abstract][Full Text] [Related]
19. Rhes, a striatal-selective protein implicated in Huntington disease, binds beclin-1 and activates autophagy.
Mealer RG; Murray AJ; Shahani N; Subramaniam S; Snyder SH
J Biol Chem; 2014 Feb; 289(6):3547-54. PubMed ID: 24324270
[TBL] [Abstract][Full Text] [Related]
20. A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease.
Cummings DM; Alaghband Y; Hickey MA; Joshi PR; Hong SC; Zhu C; Ando TK; André VM; Cepeda C; Watson JB; Levine MS
J Neurophysiol; 2012 Jan; 107(2):677-91. PubMed ID: 22072510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
